合成,抗癌活性,和对接研究的新型基-基-基混合衍生物
Javier Maldonado1, Alfonso Oliva1, Leda Guzmán1
1Instituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Valparaíso 23732223, Chile.
International journal of molecular sciences
|July 13, 2024
概括
新型抗瘤杂交物结合1,4-基和 furan 或 pyrazoline 支架显示对乳腺和结直肠癌细胞具有显著的细胞毒性活性. 这些化合物代表了针对酶通路的新化疗剂的有希望的候选者.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症生物学 癌症生物学
背景情况:
- 新型抗癌药物的开发对于有效的癌症治疗至关重要.
- 混合分子提供了一个有希望的策略,以提高治疗疗效.
- 1,4-基,基, furan 和 pyrazoline 支架被探索它们的生物活动.
研究的目的:
- 合成和评估新的抗瘤混合化合物.
- 为了研究这些混合体对抗癌症细胞系的结构-活性关系.
- 探索它们作为激酶通路抑制剂的潜力.
主要方法:
- 合成含有1,4-基和, furan 或 pyrazoline 部分的混合分子.
- 在体外评估对MCF-7 (乳腺腺癌) 和HT-29 (结肠直肠癌) 细胞系的细胞毒性活性.
- 分子对接研究,以预测与酶蛋白的结合亲和力.
- 对药物相似性和ADME属性的评估.
主要成果:
- 合成的杂交体对被测试的癌细胞系表现出显著的细胞毒性活性 (IC50:28.8124.6μM).
- 化合物4,5,6和8显示出增强的抗增殖作用,而化合物8对HT-29细胞特别有效.
- 分子对接表明了与酶标的良好相互作用,这表明了潜在的作用机制.
- 衍生品7和8表现出有利的药物相似性和ADME概况.
结论:
- 新型混合化合物具有有前途的抗瘤潜力,特别是那些包含 furan 和 pyrazoline 组的混合化合物.
- 这些衍生物显示出作为向酶通路的化疗剂的潜力.
- 化合物7和8被确定为进一步临床前开发的主要候选物.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...